Mereo BioPharma (MREO) Total Liabilities (2017 - 2026)
Mereo BioPharma (MREO) posted quarterly Total Liabilities of $6.6 million for Q1 2026, down 20.4% year-over-year from $8.2 million in Q1 2025, and up 31.17% quarter-over-quarter from $5.0 million in Q4 2025.
Mereo BioPharma (MREO) Total Liabilities (2017 - 2026) Analysis & Trends
Mereo BioPharma (MREO) has reported Total Liabilities for 10 consecutive years, with $6.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Liabilities fell 20.4% year-over-year to $6.6 million; the TTM figure through Mar 2026 stood at $6.6 million (down 20.4% YoY), while the FY2025 annual figure was $5.0 million, down 67.57% from the prior year.
- Total Liabilities grew to $6.6 million in Q1 2026 per MREO's latest filing, from $5.0 million in the prior quarter.
- Across five years, Total Liabilities topped out at $48.4 million in Q2 2022 and bottomed at $5.0 million in Q4 2025.
- Historically, Total Liabilities has averaged $17.0 million across 5 years, with a median of $15.4 million in 2024.
- Annual changes were most pronounced in 2024 — Total Liabilities dropped 3.39% — and 2025, when it tumbled 67.57%.
- Mereo BioPharma's Total Liabilities stood at $30.7 million in 2022, then slumped by 48.08% to $16.0 million in 2023, then declined by 3.39% to $15.4 million in 2024, then sank by 67.57% to $5.0 million in 2025, then surged by 31.17% to $6.6 million in 2026.
- Business Quant data shows MREO's Total Liabilities at $6.6 million in Q1 2026, $5.0 million in Q4 2025, and $7.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 3.22 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.35 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 10.03 Bn |
| 10 | Mereo BioPharma | 47.39 Mn | 47.39 Mn | - | 6.06 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.06 Mn |
| Mar 31, 2026 | 6.56 Mn |
| Dec 31, 2025 | 5.00 Mn |
| Sep 30, 2025 | 7.00 Mn |
| Jun 30, 2025 | 8.45 Mn |
| Mar 31, 2025 | 8.24 Mn |
| Dec 31, 2024 | 15.42 Mn |
| Sep 30, 2024 | 16.21 Mn |
| Jun 30, 2024 | 17.48 Mn |
| Mar 31, 2024 | 13.10 Mn |
| Dec 31, 2023 | 15.96 Mn |
| Jun 30, 2023 | 28.65 Mn |
| Dec 31, 2022 | 30.74 Mn |
| Jun 30, 2022 | 48.42 Mn |
| Dec 31, 2021 | 51.78 Mn |
| Jun 30, 2021 | 89.78 Mn |
| Dec 31, 2020 | 102.89 Mn |
| Jun 30, 2020 | 106.21 Mn |
| Dec 31, 2019 | 59.39 Mn |
| Jun 30, 2019 | 61.88 Mn |